The non-steroidal FXR agonists PX20606 and GS-9674 improve liver fibrosis and portal hypertension in rodent models of cholestatic, metabolic and toxic liver cirrhosis
T Reiberger, P Schwabl, P Supper, D Bauer, BA Payer, N Rohr-Udilova, B Podesser, C Kremoser, M Trauner · Zeitschrift für Gastroenterologie · 2016 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: FXR agonists show beneficial effects in cholestasis and NASH. We evaluated the non-steroidal FXR agonists PX20606 and GS-9674 in rodent models of toxic (CCl4), and metabolic (NASH) liver fibrosis. Methods: Toxic model: CCl4 2x/week i.p. for 12weeks. PX20606 (10 mg/kg/day) was given from weeks4 – 12 of CCl4. NASH model: choline-deficient high-fat diet plus repeated NaNO2 (25 mg/kg i.p., 2x/week) for 10 weeks. GS-9674 (10 mg/kg/day or 30 mg/kg/day) was gavaged from weeks4 – 10, with/without propranolol (PROP, 25 mg/kg). At end of treatment, mean arterial pressure (MAP), heart rate (HR), portal pressure…
